March 22, 2019 09:24 AM EDT

Novartis' Alcon unit set for Swiss/NYSE debut on April 9; Novo's keenly anticipated oral GLP-1 submitted for speedy US review

→ Novartis’ eye care business Alcon — being spun off by the Swiss drugmaker — will start trading on the Swiss market and NYSE on

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

No­var­tis' Al­con unit set for Swiss/NYSE de­but on April 9; Novo's keen­ly an­tic­i­pat­ed oral GLP-1 sub­mit­ted for speedy US re­view